Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Infrared Sciences was a medical device company focused on the development and commercialization of infrared imaging technology for breast cancer detection. Its primary product, the Sentinel BreastScan, was an FDA-cleared diagnostic tool designed to be used as an adjunct to mammography. The system utilized Digital Infrared Imaging (DII) to detect heat patterns and vascular changes that may indicate the presence of a tumor. By providing a non-invasive, radiation-free physiological assessment, the company sought to enhance early detection rates, especially in younger women and those with dense breast tissue. In 2010, the company was acquired by LumaSense Technologies, which integrated the technology into its thermal imaging and sensing business.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Infrared Sciences.